Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03239561 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
A Early Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
NCT03239561 is a Early Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 15 participants.
The verdict
NCT03239561, a Early Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The primary objectives of this study are to characterize \[18F\]molecular neuroimaging (MNI)-1020, a positron emission tomography (PET) radioligand for imaging tau pathology, to visually and quantitatively assess and compare brain uptake and pharmacokinetics of \[18F\]MNI-1020 in participants with probable Alzheimer's disease (AD) and compare with age matched healthy participants, to evaluate the safety of a single injection of \[18F\]MNI-1020 and to compare the distribution of tau (using \[18F\]MNI-1020) and amyloid beta (using florbetapir) in participants with probable AD.
Interventions
- DRUG [18F]MNI-1020
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-09-06 |
| Est. Completion | 2018-04-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03239561
The ClinicalTrials.gov registry entry for NCT03239561 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]MNI-1020 is the first listed.
NCT03239561 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03239561 about?
NCT03239561 is a clinical study titled "Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants". The primary objectives of this study are to characterize \[18F\]molecular neuroimaging (MNI)-1020, a positron emission tomography (PET) radioligand for imaging tau pathology, to visually and quantitatively assess and compare brain uptake and pharmacokinetics of \[18F\]MNI-1020 in participants with p...
What is the current status of trial NCT03239561?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2017-09-06. Estimated completion is 2018-04-30.
What interventions are being tested in trial NCT03239561?
The interventions under investigation include: [18F]MNI-1020 (DRUG).
Who is sponsoring clinical trial NCT03239561?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.